Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Laura Amanda Vallejo-Aparicio
Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Related publications
Prs38 - Cost-Consequence Analysis of Fluticasone Furoate/Vilanterol for Asthma Management in Spain: An Analysis Based on the Salford Lung Study in Asthma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prs48 - Cost – Effectiveness Analysis of Vilanterol/Fluticasone Furoate for Asthma Treatment in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients
American Journal of Respiratory and Critical Care Medicine
Pulmonary
Critical Care
Respiratory Medicine
Intensive Care Medicine
A Comparison of the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol With Twice-Daily Fluticasone Propionate/Salmeterol in Moderate to Very Severe COPD
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Single-Inhaler Triple Therapy Utilizing the Once-Daily Combination of Fluticasone Furoate, Umeclidinium and Vilanterol in the Management of COPD: The Current Evidence Base and Future Prospects
Therapeutic Advances in Respiratory Disease
Pulmonary
Respiratory Medicine
Pharmacology
A Randomised Trial of Fluticasone Furoate/Vilanterol (50/25 Μg; 100/25 Μg) on Lung Function in COPD
Respiratory Medicine
Pulmonary
Respiratory Medicine
Benefit and Safety of Fluticasone Furoate/Vilanterol in the Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD) According to Baseline Patient Characteristics and Treatment Subgroups
Respiratory Medicine
Pulmonary
Respiratory Medicine
Corrigendum to “Fluticasone Furoate/Vilanterol (100/25; 200/25 Μg) Improves Lung Function in COPD: A Randomised Trial” [Respir Med 107 (2013) 550–559]
Respiratory Medicine
Pulmonary
Respiratory Medicine
Corrigendum to “A Randomised Trial of Fluticasone Furoate/Vilanterol (50/25 Μg; 100/25 Μg) on Lung Function in COPD” [Respir Med, 107 (2013) 560–569]
Respiratory Medicine
Pulmonary
Respiratory Medicine
